On the basis of these findings, we herein compare the efficacies and safeties of CPIT with n-IFN-β as induction therapy followed by triple therapy with PI with PR and CPIT with n-IFN-β followed by PR alone in CHC patients with genotype 1b and high viral loads. This evidence concerns the gene IFNB1 and cryohydrocytosis.